CUBIST PHARMS LLC
Big PharmaCUBIST PHARMS LLC is a major pharmaceutical company focused on Infectious Disease, Dermatology. Key products include ZERBAXA.
CUBIST PHARMS LLC's Key Drugs
CUBIST PHARMS LLC's core commercial portfolio centers on ZERBAXA, DIFICID, SIVEXTRO, spanning Infectious Disease and Dermatology — its most strategically important drugs approved in the last 15 years.
CUBIST PHARMS LLC's Recent FDA Approvals
New NDA/BLA approvals for CUBIST PHARMS LLC over the last two years — novel drugs only, excluding generics and label supplements.
CUBIST PHARMS LLC's Therapeutic Areas
CUBIST PHARMS LLC's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CUBIST PHARMS LLC's Top Competitors
CUBIST PHARMS LLC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CUBIST PHARMS LLC Pipeline Snapshot
Active clinical trials for CUBIST PHARMS LLC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ZERBAXA leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling